- Previous Close
15.75 - Open
15.69 - Bid 15.50 x --
- Ask 16.00 x --
- Day's Range
15.69 - 16.00 - 52 Week Range
10.00 - 35.00 - Volume
19,127 - Avg. Volume
406,293 - Market Cap (intraday)
15.426M - Beta (5Y Monthly) 1.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators in the United Kingdom, the United States, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; CholBiome, a food supplement for reducing cholesterol and blood pressure; LPGOS, a galactooligosaccharide that is used in food products and applications, which helps reduce cardiovascular risk factors and enhance health; and Sweetbiotix, a low calorie sweetener for food and beverages. The company's products prevent and manage chronic lifestyle disorders, including obesity, hypercholesterolemia, and diabetes. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.
optibiotix.comRecent News: OPTI.L
View MorePerformance Overview: OPTI.L
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPTI.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPTI.L
View MoreValuation Measures
Market Cap
15.43M
Enterprise Value
14.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
29.01
Price/Book (mrq)
2.09
Enterprise Value/Revenue
25.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.93%
Return on Equity (ttm)
-36.34%
Revenue (ttm)
569k
Net Income Avi to Common (ttm)
-2.98M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
1.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-932.62k